Both are part of a new class of drugs known as GLP-1 receptor agonists, but they have some key differences in how they work and their overall efficacy
Robinson, T
Prior use of other medications or supplements that affect inflammation, bone density, or muscle metabolism can amplify joint symptoms during GLP-1 therapy
Typical progression may include: 0.25 mg once weekly 0.5 mg once weekly 1 mg once weekly 1.7 mg once weekly 2.4 mg once weekly (maintenance dose) This gradual increase helps the body adapt to semaglutide therapy
Drugmaker Novo Nordisk told CNN in July in response to these claims that GLP-1 agonists have been studied extensively and used for years
Links: IgNobel prizes: IgNobel Prizes were recently awarded: www.ncbi.nlm.nih.gov/pubmed/40601364 Colchicine for secondary prevention of CHD: Green tea and drug absorption: Episode 189: asthma rescue, exercise for cancer, digitoxin, and minor stroke treatment This week Gary, Kate, Henry and Mark discuss 4 important new studies that are potential POEMs: A new(ish) rescue therapy for asthma, IV thrombolytics for adults with acute minor stroke, whether exercise reduces cancer mortality, and digitoxin (with a t!) as add-on therapy for adults with heart failure
